Hjem › Schizofreni › Texas
Kliniske studier for Schizofreni i Texas
34 studier for Schizofreni søker deltakere på steder i Texas.
Byer i Texas
- Houston13 studier
- Austin13 studier
- Richardson9 studier
- Grand Prairie8 studier
- Dallas8 studier
- Fort Worth3 studier
Offisiell studietekst (engelsk)
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Haracec Clinical Research, El Paso
- C-Trilogy Outreach, Longview
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07101094A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
- Community Clinical Research, Inc., Austin
- Pillar Clinical Research, LLC, Richardson
RekruttererFase 1
Alder 18 til 55 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07615426Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Local Institution - 0049, Austin
- Local Institution - 0194, Dallas
- Pillar Clinical Research - Richardson, Richardson
RekruttererFase 3
Alder 18 til 65 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07686263Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- Texas Research Group, Coppell
- PsyMed Solutions, Fort Worth
- Kaleidoscope Clinical Research, Houston
- og 3 flere
RekruttererFase 3
Alder 5 til 17 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06229210NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Site, Austin
- Neurocrine Clinical Site, DeSoto
- Neurocrine Clinical Site, Houston
RekruttererFase 3
Alder 18 til 65 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07114874Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
- Neurocrine Clinical Site, DeSoto
RekruttererFase 3
Alder 18 til 65 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07227818Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
- TG Therapeutics Investigational Trial Site, Richardson
RekruttererFase 2
Alder 18 til 60 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07680946A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Local Institution - 0149, Dallas
- VAST Clinical Research, Garland
- Local Institution - 0169, Houston
- og 2 flere
RekruttererFase 3
Alder 5 til 17 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07424404A Study of Brenipatide in Adult Participants With Schizophrenia
- Adams Clinical Dallas, DeSoto
- Re:Cognition Health - Fort Worth, Fort Worth
RekruttererFase 2
Alder 18 til 55 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07410507A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Austin
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT07105111A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
- Pillar Clinical Research, LLC, Richardson
RekruttererFase 1
Alder 18 til 55 · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07734493Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)
- The University of Texas Health Science Center, Houston, Houston
Rekrutterer
Alder 22 til 65 · Alle kjønn · Oppdatert 16. sep. 2026 · NCT05276050A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
- Community Clinical Research - Cross Park Drive /ID# 272977, Austin
- Pillar Clinical Research - Richardson /ID# 275715, Richardson
RekruttererFase 2
Alder 18 til 65 · Alle kjønn · Oppdatert 15. sep. 2026 · NCT0714591852-week Open Label Safety-Tolerability Study
- Adams Clinical, DeSoto
- Pillar Clinical Research, Richardson
RekruttererFase 3
Alder 18 til 65 · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07369154A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- VAST Clinical Research, Garland
- Local Institution - 0120, Houston
- Local Institution - 0066, Spring
RekruttererFase 3
Alder 13 til 17 · Alle kjønn · Oppdatert 4. sep. 2026 · NCT07288567A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
- Community Clinical Research, Austin
RekruttererFase 1
Alder 18 til 55 · Alle kjønn · Oppdatert 2. sep. 2026 · NCT07061288A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, Austin
- Clinical Site, DeSoto
- Clinical Site, Richardson
RekruttererFase 2
Alder 18 til 65 · Alle kjønn · Oppdatert 1. sep. 2026 · NCT07459647Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- Local Institution - 0016, Austin
- Local Institution - 0050, Dallas
- Local Institution - 0021, Fort Worth
- og 10 flere
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 19. aug. 2026 · NCT07379827Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
- BioXcel Clinical Research Site, DeSoto
RekruttererFase 1
Alder 10 til 17 · Alle kjønn · Oppdatert 11. aug. 2026 · NCT05025605Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia
- The University of Texas Health Science Center at Houston, Houston
Rekrutterer
Alder 18 til 60 · Alle kjønn · Oppdatert 5. aug. 2026 · NCT07060066Alternative Stimulation Mode and Location for Auditory Hallucination Neuromodulation Treatment
- The University of Texas Health Science Center at Houston, Houston
Rekrutterer
Alder 18 til 50 · Alle kjønn · Oppdatert 3. aug. 2026 · NCT02916810Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 2)
- The University of Texas Health Science Center, Houston, Houston
Rekrutterer
Alder 18 til 60 · Alle kjønn · Oppdatert 7. jul. 2026 · NCT06961916Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
- The University of Texas Health Science Center, Houston, Houston
Rekrutterer
Alder 18 til 60 · Alle kjønn · Oppdatert 7. jul. 2026 · NCT06345963A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Community Clinical Research, Austin
RekruttererFase 2
Alder 18 til 55 · Alle kjønn · Oppdatert 23. jun. 2026 · NCT07191483Deep Brain Stimulation for Psychosis
- UT Southwestern Medical Center, Dallas
Rekrutterer
Alder 22 til 70 · Alle kjønn · Oppdatert 9. jun. 2026 · NCT06257056A Study to Evaluate the Effect of KarXT on Urological Safety
- Local Institution - 0001, Austin
- InSite Clinical Research, DeSoto
RekruttererFase 4
Alder 18 til 65 · Alle kjønn · Oppdatert 3. jun. 2026 · NCT07221877CLOZAPINE Response in Biotype-1
- UT Southwestern Medical Center, Dallas
RekruttererFase 4
Alder 18 til 60 · Alle kjønn · Oppdatert 11. mai 2026 · NCT04580134Database Registry for Neural Network Biomarkers in Psychosis
- University of Texas Southwestern Medical Center, Dallas
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 18 til 60 · Alle kjønn · Oppdatert 23. apr. 2026 · NCT01409109Ocrelizumab for Psychosis by Autoimmunity
- Houston Methodist Research Institute, Houston
RekruttererFase 1/2
Alder 18 til 35 · Alle kjønn · Oppdatert 1. apr. 2026 · NCT03971487Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- University of Texas Southwestern Medical Center, Dallas
RekruttererObservasjonsstudie
Alder 18 til 40 · Alle kjønn · Oppdatert 10. mar. 2026 · NCT06740383NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, Austin
- Neurocrine Clinical Site, DeSoto
- Neurocrine Clinical Site, Houston
RekruttererFase 3
Alder 18 til 65 · Alle kjønn · Oppdatert 6. mar. 2026 · NCT06963034Randomized Clinical Trial of iTEST: A Blended Intervention Targeting Introspective Accuracy
- University of Texas at Dallas, Dallas
Rekrutterer
Alder 18 til 65 · Alle kjønn · Oppdatert 23. jan. 2026 · NCT07098169Randomized Withdrawal Study in Patients With Schizophrenia
- Vanda Investigational Site, Austin
- Vanda Investigational Site, Houston
- Vanda Investigational Site, Irving
- og 1 flere
RekruttererFase 3
Alder 18 til 65 · Alle kjønn · Oppdatert 12. jan. 2026 · NCT06961968Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- Reviva site, Austin
- Reviva site, Richardson
RekruttererFase 3Frivillige helsepersonell ønskes velkommen
Alder 18 til 65 · Alle kjønn · Oppdatert 19. des. 2024 · NCT05184335Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.